Abstract Library

#4548 Carcinoid heart disease in patients with carcinoid syndrome and metastatic small intestinal neuroendocrine tumours: A single centre experience

Introduction: Carcinoid heart disease (CHD) is a significant complication of carcinoid syndrome (CS) in patients with small intestinal neuroendocrine tumours (SINET). Management is complex and more data is needed.

Conference:

Presenting Author:

Authors: Salman M, Waters M, Abbott C, Quinn M, O'Toole D,

Keywords: carcinoid heart disease, carcinoid syndrome, NET, neuroendocrine tumour, small intestinal NET,

#4156 Status of the ongoing SORENTO clinical trial: Assessing efficacy and safety of high-exposure octreotide subcutaneous depot in patients with GEP-NET

Introduction: Somatostatin receptor ligands (SRLs) are first-line standard of care therapies for gastroenteropancreatic neuroendocrine tumors (GEP-NET). Retrospective data suggest higher-dose SRLs may benefit patients with GEP-NET.

Conference:

Presenting Author: Singh S

Authors: Singh S, Capdevila J, Ang Chan J, de Herder W, Grozinsky-Glasberg S,

Keywords: CAM2029, GEP-NET, high plasma exposure, octreotide, randomised active-controlled, somatostatin receptor ligands, SORENTO,

#3944 Compare the optimal TNM staging of resectable functional and non-functional pancreatic neuroendocrine tumors

Introduction: At present, the European Neuroendocrine Tumor Society (ENETS) and the American Joint Committee on Cancer (AJCC) are two main tumor TNM staging systems. However, the ENETS and AJCC TNM staging systems are different in some aspects when applied to p-NETs.

Conference:

Presenting Author: Wang Z

Authors: Xie Z, Wang Z, Cao D, Ke N,

Keywords: p-NETs, ENETS stage, AJCC stage, prognosis,

#3879 Molecular characterization of extrapulmonary, advanced neuroendocrine carcinomas and mixed adeno-neuroendocrine carcinomas – The NIRVANA study

Introduction: Extrapulmonary (EP) poorly differentiated neuroendocrine carcinomas (NECs) and mixed adeno-neuroendocrine carcinomas (MANECs) are aggressive neoplasms with dismal prognosis.

Conference:

Presenting Author: Spada F

Authors: Spada F, Pisa E, Ranghiero A, Frassoni S, Bagnardi V,

Keywords: poorly differentiated, extrapulmonary, NGS, NEC, biomarker, NEN,

#3585 Belzutifan, an oral hypoxia-inducible factor 2α inhibitor, for Von Hippel-Lindau disease–associated pancreatic neuroendocrine tumors

Introduction: Constitutive activation of hypoxia-inducible factor 2α (HIF-2α) drives tumor growth, which include pancreatic lesions (serous cystadenomas and pancreatic neuroendocrine tumors [pNETs]), in Von Hippel-Lindau (VHL) disease. Belzutifan, an oral HIF-2α inhibitor, is approved for patients with VHL disease based on the results of this ongoing open-label phase 2 study (NCT03401788).

Conference:

Presenting Author:

Authors: Else T, Jonasch E, Iliopoulos O, Rathmell W, Narayan V,

Keywords: VHL, pancreatic neuroendocrine tumor, pNET, HIF-2α, belzutifan,